218 related articles for article (PubMed ID: 11597985)
21. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
Vajkoczy P; Farhadi M; Gaumann A; Heidenreich R; Erber R; Wunder A; Tonn JC; Menger MD; Breier G
J Clin Invest; 2002 Mar; 109(6):777-85. PubMed ID: 11901186
[TBL] [Abstract][Full Text] [Related]
22. Stem cells combined with gene transfer for therapeutic vasculogenesis: magic bullets?
Nabel EG
Circulation; 2002 Feb; 105(6):672-4. PubMed ID: 11839618
[No Abstract] [Full Text] [Related]
23. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.
Wang D; Lehman RE; Donner DB; Matli MR; Warren RS; Welton ML
Am J Physiol Gastrointest Liver Physiol; 2002 Jun; 282(6):G1088-96. PubMed ID: 12016135
[TBL] [Abstract][Full Text] [Related]
24. The neural tube patterns vessels developmentally using the VEGF signaling pathway.
Hogan KA; Ambler CA; Chapman DL; Bautch VL
Development; 2004 Apr; 131(7):1503-13. PubMed ID: 14998923
[TBL] [Abstract][Full Text] [Related]
25. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.
Maisonpierre PC; Suri C; Jones PF; Bartunkova S; Wiegand SJ; Radziejewski C; Compton D; McClain J; Aldrich TH; Papadopoulos N; Daly TJ; Davis S; Sato TN; Yancopoulos GD
Science; 1997 Jul; 277(5322):55-60. PubMed ID: 9204896
[TBL] [Abstract][Full Text] [Related]
26. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
27. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
28. The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed during the remodeling of free tendon grafts in sheep.
Petersen W; Unterhauser F; Pufe T; Zantop T; Südkamp NP; Weiler A
Arch Orthop Trauma Surg; 2003 May; 123(4):168-74. PubMed ID: 12734715
[TBL] [Abstract][Full Text] [Related]
29. Building better vasculature.
Bruick RK; McKnight SL
Genes Dev; 2001 Oct; 15(19):2497-502. PubMed ID: 11581154
[No Abstract] [Full Text] [Related]
30. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix.
Libby P; Schönbeck U
Circ Res; 2001 Aug; 89(3):195-7. PubMed ID: 11485968
[No Abstract] [Full Text] [Related]
31. Vessels and nerves: marching to the same tune.
Weinstein BM
Cell; 2005 Feb; 120(3):299-302. PubMed ID: 15707889
[TBL] [Abstract][Full Text] [Related]
32. Role of growth factors and their receptors in proliferation of microvascular endothelial cells.
Suhardja A; Hoffman H
Microsc Res Tech; 2003 Jan; 60(1):70-5. PubMed ID: 12500263
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of vascular development.
Sato T
Circ Res; 2001 Feb; 88(2):127-8. PubMed ID: 11157660
[No Abstract] [Full Text] [Related]
34. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
35. Molecular control of physiological skin angiogenesis.
Odorisio T; Failla CM; Zambruno G
Eur J Dermatol; 2002; 12(6):VII-X. PubMed ID: 12506892
[No Abstract] [Full Text] [Related]
36. [Vascular endothelial growth factor and nitric oxide].
Liu YQ; Zhou AR
Sheng Li Ke Xue Jin Zhan; 2000 Jan; 31(1):69-71. PubMed ID: 12532773
[No Abstract] [Full Text] [Related]
37. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
38. Dissection of monocyte and endothelial activities by using VEGF-receptor specific ligands.
Clauss M; Pipp F; Issbrücker K; Weich H; Heil M; Schaper W
Adv Exp Med Biol; 2003; 522():75-82. PubMed ID: 12674212
[No Abstract] [Full Text] [Related]
39. Liver organogenesis promoted by endothelial cells prior to vascular function.
Matsumoto K; Yoshitomi H; Rossant J; Zaret KS
Science; 2001 Oct; 294(5542):559-63. PubMed ID: 11577199
[TBL] [Abstract][Full Text] [Related]
40. What guides early embryonic blood vessel formation?
Weinstein BM
Dev Dyn; 1999 May; 215(1):2-11. PubMed ID: 10340752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
